CHRS - Coherus Oncology, Inc. Stock Analysis & Valuation

Coherus Oncology, Inc. (CHRS) trades at $0.83 with an EquitAI Valuation DNA score of 4/10 and Quality score of 2/10. These scores evaluate balance sheet leverage, free cash flow generation, and fundamental multiples against historical benchmarks.

Wall Street analysts have a consensus 12-month price target of $6.0 for Coherus Oncology, Inc. (CHRS), representing an implied 625.2% upside from its current trading level of $0.83 with an average rating of Buy based on 4 analyst ratings. Individual analyst price targets range from a low of $1.1 to a high of $11.0, with a median forecast of $6.0. EquitAI benchmarks analyst consensus projections against intrinsic Financial DNA valuation pillars.

Coherus Oncology, Inc. does not currently pay a regular dividend yield, prioritizing capital reinvestment into operations, product development, and balance sheet strength.

EquitAI provides quantitative financial research, algorithmic DNA scores, and SEC contextual analytics for informational and research purposes. It does not constitute personalized financial advice or broker-dealer investment recommendations.